Alastair Noyce
Overview
Explore the profile of Alastair Noyce including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
28
Citations
507
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mahlknecht P, Leiter S, Horlings C, Schwarzova K, Egner I, Stockner H, et al.
Mov Disord Clin Pract
. 2024 Nov;
12(2):203-209.
PMID: 39558636
Background: Preferences for risk disclosure in population-based studies assessing Parkinson's disease (PD) risk have not been assessed so far. Objectives: To examine preferences for risk disclosure in a subset of...
2.
Li X, Gill A, Panzarasa P, Bestwick J, Schrag A, Noyce A, et al.
JMIR Form Res
. 2024 May;
8:e51977.
PMID: 38788211
Background: There is evidence that social interaction has an inverse association with the development of neurodegenerative diseases. PREDICT-Parkinson Disease (PREDICT-PD) is an online UK cohort study that stratifies participants for...
3.
Patyjewicz M, Mair D, Zaloum S, Onen B, Walton J, Dobson R, et al.
BMJ Neurol Open
. 2024 May;
6(1):e000619.
PMID: 38757110
Background: The study aimed to elucidate the prevalence of nitrous oxide (N2O) usage in patients with unexplained venous thromboembolism (VTE), highlighting the potential association with hyperhomocysteinaemia (HHcy). Methods: We conducted...
4.
Embedding Patient Input in Outcome Measures for Long-Term Disease-Modifying Parkinson Disease Trials
Gonzalez-Robles C, Bartlett M, Burnell M, Clarke C, Haar S, Hu M, et al.
Mov Disord
. 2023 Dec;
39(2):433-438.
PMID: 38140767
Background: Clinical trials of disease-modifying therapies in PD require valid and responsive primary outcome measures that are relevant to patients. Objectives: The objective is to select a patient-centered primary outcome...
5.
Toffoli M, Chohan H, Mullin S, Jesuthasan A, Yalkic S, Koletsi S, et al.
Neurobiol Dis
. 2023 Nov;
188:106343.
PMID: 37926171
Background: Variants in the GBA1 gene cause the lysosomal storage disorder Gaucher disease (GD). They are also risk factors for Parkinson's disease (PD), and modify the expression of the PD...
6.
Bernard Healey S, Giovannoni G, Noyce A, Dobson R, Jacobs B
Brain
. 2023 Oct;
147(2):e17-e21.
PMID: 37850390
No abstract available.
7.
Gonzalez-Robles C, Weil R, van Wamelen D, Bartlett M, Burnell M, Clarke C, et al.
J Parkinsons Dis
. 2023 Aug;
13(6):1011-1033.
PMID: 37545260
Background: Multi-arm, multi-stage (MAMS) platform trials can accelerate the identification of disease-modifying treatments for Parkinson's disease (PD) but there is no current consensus on the optimal outcome measures (OM) for...
8.
Frisoni G, Altomare D, Ribaldi F, Villain N, Brayne C, Mukadam N, et al.
Lancet Reg Health Eur
. 2023 Mar;
26:100576.
PMID: 36895446
Observational population studies indicate that prevention of dementia and cognitive decline is being accomplished, possibly as an unintended result of better vascular prevention and healthier lifestyles. Population aging in the...
9.
Bramich S, Verdi K, Salmon K, Noyce A, Alty J
Br J Gen Pract
. 2022 Dec;
73(726):40-42.
PMID: 36543550
No abstract available.
10.
Krohn L, Heilbron K, Blauwendraat C, Reynolds R, Yu E, Senkevich K, et al.
Nat Commun
. 2022 Dec;
13(1):7496.
PMID: 36470867
Rapid-eye movement (REM) sleep behavior disorder (RBD), enactment of dreams during REM sleep, is an early clinical symptom of alpha-synucleinopathies and defines a more severe subtype. The genetic background of...